NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan and Trautec have Conducted An Extensive Investigation Across the Recombinant Type XVII Collagen Industry Chain - Revolutionizing Skin Repair with Recombinant Type XVII Collagen in China’s Growing Markets - Trautec.us
Frost & Sullivan and Trautec have Conducted An Extensive Investigation Across the Recombinant Type XVII Collagen Industry Chain

 

NewswireTODAY - /newswire/ - San Antonio, TX, United States, 2024/01/29 - Revolutionizing Skin Repair with Recombinant Type XVII Collagen in China’s Growing Markets - Trautec.us.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Recent breakthroughs in synthetic biology have enabled the production of recombinant Type XVII collagen, a promising therapeutic protein and anti-aging raw material.

Collagen, abundantly found in human tissues, is essential for maintaining tissue structure and function. Type XVII collagen plays a pivotal role, connecting the cell’s cytoskeleton to the basement membrane, and ensuring skin integrity. Recent research highlights its involvement in skin diseases, stem cell regulation, and aging-related issues like hair loss and graying. In skin wound repair, type XVII collagen significantly influences stem cell migration, proliferation, and differentiation. Advances in synthetic biology enable the production of recombinant type XVII collagen, showcasing substantial potential as a novel therapeutic protein and anti-aging raw material.

Frost & Sullivan and Trautec (trautec.us) have conducted an extensive investigation across the recombinant type XVII collagen industry chain, exploring the potential of type XVII collagen in skin repair and anti-aging. Together, they co-published the ‘Recombinant Type XVII Collagen Whitepaper, ’ which focuses on the industry in China and highlights new growth opportunities.

Medical dressing and skincare products are the main sectors for type XVII collagen applications. Based on Frost & Sullivan’s investigation and calculation, the market size of medical dressings in China has shown strong growth as the demand for skin repair grows. The market size of medical dressings in China increased from 6.7 billion CNY in 2017 to 25.9 billion CNY in 2021 and is expected to reach 97.9 billion CNY in 2027. The market penetration of medical dressings based on recombinant collagen protein increased from 5.2% in 2017 to 18.5% in 2021, and it is projected to further rise to 26.1% by 2027. The market size of medical dressings based on recombinant collagen protein was 4.8 billion CNY in 2021 and is expected to increase to 25.5 billion CNY in 2027.

The application of bioactive ingredients has significantly propelled the growth of the functional skincare market in China over the past few years. Market size, measured by retail sales, escalated from CNY 13.3 billion in 2017 to CNY 30.8 billion in 2021, with projected growth to CNY 211.8 billion by 2027. Given the distinct advantages of recombinant collagen over collagen of animal origin, the penetration rate of collagen-based functional skincare products increased from 6.3% in 2017 to 14.9% in 2021, with expectations to reach 30.5% by 2027. The market size of recombinant collagen-based functional skincare products advanced from CNY 800 million in 2017 to CNY 4.6 billion in 2021, with projected growth to CNY 64.5 billion by 2027.

Trautec has pioneered breakthroughs in Type XVII recombinant collagen, contributing to innovative medical devices and aligning with the YY/T1849 industry standard. With over 60 patent applications and significant investments, including Shiseido’s Series A funding of nearly 200 million CNY and a Series B fundraising of CNY 200 million led by L Catterton, Trautec has marked industry milestones. Their recent accomplishment of expressing recombinant human type III collagen using yeast sets them apart as industry pioneers. Trautec, with large-scale, eco-friendly production of collagen types I, II, III, and XVII SRHC, has expanded globally, securing partnerships with 30+ cosmetic and pharmaceutical leaders.

About Frost & Sullivan

Frost & Sullivan’s Growth Pipeline Engine (frost.com), transformational strategies, and best-practice models drive the generation, evaluation, and implementation of powerful growth opportunities.

About Trautec

Jiangsu Trautec Medical Technology Co., Ltd. (“Trautec”) is a synthetic bioscience and technology company focusing on the research and development, production, and sales of new biomaterials and innovative protein / nucleic acid drugs with nearly 40 years of experience in the medical device industry. Anchored in its vision of building an intelligent platform for synthetic biology, Trautec aims to create a healthier future by bringing technology closer to life.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan and Trautec have Conducted An Extensive Investigation Across the Recombinant Type XVII Collagen Industry Chain

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Type XVII Collagen | Frost & Sullivan
Contact: María Alejandra Briceño 
maria.briceno[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development
Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations
Ipsen and Skyhawk Therapeutics Announce RNA Targeting Research Collaboration in Rare Neurological Diseases
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer At AACR 2024
Bruker Showcases High-Performance Solutions at Analytica 2024 for Research and Analysis in Applied, Industrial and Biopharma Laboratories
STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests
ONO Implements Oracle's CTMS for Global Centralized Management of Clinical Trials
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors
Bruker Completes Acquisition of Optical Cell Imaging Company Phasefocus
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
SCHOTT Pharma Offers Complete Testing Suite for Container Selection and Drug Submission Preparation
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
Ipsen’s Onivyde® Regimen, A Potential New Standard-of-care First-line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Bushu Pharma Recognized with Frost & Sullivan’s 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow, Inc.





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)